StockNews.AI

AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation

StockNews.AI • 2 hours

PTSDHLTHSAVA
High Materiality8/10

Information

NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Compa...

Original source

AI Summary

AtaiBeckley's recent presentations at the ACNP meeting spotlighted BPL-003's rapid, sustained antidepressant effects in treatment-resistant depression, indicating a strong push towards Phase 3 trials. This recognition could lead to heightened investor interest and potential partnerships, propelling AtaiBeckley's stock performance.

Sentiment Rationale

The strong data presentation and FDA designation elevate investor sentiment, reminiscent of past biotech surges post-positive trial results, suggesting potential stock price appreciation.

Trading Thesis

Investors should consider accumulating ATAI in anticipation of upcoming Phase 3 trial announcements.

Market-Moving

  • BPL-003's inclusion as a Hot Topic at ACNP may attract investor attention.
  • Positive Phase 2b results could facilitate quicker Phase 3 trial initiation.
  • FDA Breakthrough designation enhances attractiveness for both investors and partners.
  • Strong engagement in clinical discussions may increase ATAI's visibility in the biotech sector.

Key Facts

  • AtaiBeckley presented promising BPL-003 data at a major neuropsychopharmacology meeting.
  • BPL-003 shows rapid antidepressant effects in treatment-resistant depression patients.
  • The company seeks further Phase 3 trials based on positive Phase 2b results.
  • 5-MeO-DMT's therapeutic potential for mood disorders emphasized in preclinical studies.
  • BPL-003 has received FDA Breakthrough Therapy designation, enhancing its development profile.

Companies Mentioned

  • AtaiBeckley Inc. (ATAI): Recent clinical data could bolster stock price.
  • Kadima Neuropsychiatry Institute: Collaborative presentation enhances BPL-003's credibility.
  • UC San Diego: Association with recognized academic drive reinforces AtaiBeckley's scientific reputation.

Corporate Developments

This article falls under 'Corporate Developments' as it outlines AtaiBeckley's recent clinical achievements and strategic positioning in mental health therapies, showcasing its commitment to innovation and growth within the biotechnology sector.

AtaiBeckley Presents Groundbreaking Research at the 64th Annual ACNP Meeting

NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI), a clinical-stage biotechnology company dedicated to improving mental health treatments, announced its participation in the 64th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), held from January 12 to 15, 2026, in Nassau, The Bahamas. The company showcased innovative clinical and preclinical research through two poster presentations and a notable Hot Topic Presentation.

Key Findings from Clinical Research

Dr. David Feifel, Professor Emeritus of Psychiatry at the University of California, San Diego, and Founder of the Kadima Neuropsychiatry Institute, presented pivotal efficacy and safety data from AtaiBeckley’s Phase 2b clinical trial of BPL-003 (mebufotenin benzoate) nasal spray for patients with treatment-resistant depression (TRD). His poster, titled ‘Rapid Antidepressant Effect of Intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine) in Treatment-Resistant Depression: A Phase 2b Double-Blind Study,’ was selected for the prestigious Hot Topics Session, highlighting the study's compelling findings.

The study demonstrated that a single dose of 8 mg or 12 mg of BPL-003 achieved a significant and sustained antidepressant effect compared to a 0.3 mg control dose at all measured time points. Both dosage levels were well tolerated, emphasizing the therapeutic potential of intranasal BPL-003 for TRD and the necessity for further Phase 3 trials.

Insights from Preclinical Research

In parallel, Dr. Michelle Kokkinou, Senior Scientist in Non-Clinical Development at AtaiBeckley, presented a preclinical study titled ‘The Pharmacological, Pharmacokinetic and Potential Neuroplasticity-Related Profile of 5-MeO-DMT (mebufotenin), a 5-HT Receptor Agonist for the Treatment of Mood Disorders.’ This research evaluated the pharmacological properties and potential therapeutic mechanisms of 5-MeO-DMT. The findings point to its significance in addressing mood disorders by enhancing neuroplasticity, a crucial factor for patients affected by these conditions.

Company Insights and Future Directions

Commenting on the event, Dr. Kevin Craig, Chief Medical Officer at AtaiBeckley, expressed his optimism, stating, “We are delighted that our Phase 2b BPL-003 results were selected for poster presentation and recognized as a Hot Topic at ACNP. This distinction underscores the strength and impact of our clinical findings in treatment-resistant depression. We’re equally pleased that our preclinical work on 5-MeO-DMT was accepted for presentation, showcasing our commitment to breakthroughs in mental health.”

About BPL-003 and AtaiBeckley's Mission

BPL-003, a proprietary intranasal formulation of mebufotenin benzoate, is designed to deliver rapid and durable effects from a single dose with a short psychedelic duration. Currently under investigation for treatment-resistant depression (TRD) and alcohol use disorder (AUD), BPL-003 has been awarded Breakthrough Therapy designation by the U.S. Food and Drug Administration.

AtaiBeckley, formed by the strategic merger of atai Life Sciences N.V. and Beckley Psytech Limited in November 2025, aims to transform patient outcomes through innovative mental health treatments. The company's portfolio includes BPL-003, as well as VLS-01 (DMT buccal film) and EMP-01 (oral R-MDMA), all in Phase 2 clinical development. AtaiBeckley also pursues a drug discovery program targeting non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD.

Stay Updated

To keep up with the latest developments in AtaiBeckley's mission towards mental health innovations, visit www.ataibeckley.com or follow the company on LinkedIn and X.

Forward-Looking Statements

This article contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. While AtaiBeckley aims to provide accurate predictions, actual results may differ due to various risks and uncertainties related to product development and market performance. For a comprehensive understanding of risks, please refer to the latest Annual Report on Form 10-K filed with the SEC.

Contact Information

Related News